Survey on Aimovig for CADTH
(part 2: experience with Aimovig)
CADTH (Canadian Agency for Drugs and Technology in Health) is currently evaluating the clinical value of Aimovig (erenumab) for the prevention of migraine. The input from patient groups is solicited.
Migraine Canada has already done a survey on the impact of migraine and the effectiveness of available treatments to support the need for new preventive options. Some of you might have participated to this survey. Now, we need to finalize our work by documenting the experience of Canadians with Aimovig.
Aimovig has been available in Canada since December 2018. It is accessible via a patient support program called Aimovig GO, allowing Novartis to pay for the drug while the drug coverage is determined by private and public payers.
If you have tried Aimovig for migraine prevention, we need your input!
Please fill the following short survey so we can tell CADTH about the Canadian experience with this product.
The Migraine Canada Team